Status:
COMPLETED
Casodex vs Placebo in Non-Metastatic Early Prostate Cancer
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Scandinavian Prostate Cancer Group
Conditions:
Non-Metastatic Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy o...
Eligibility Criteria
Inclusion
- Clinical diagnosis of non-metastatic cancer of the prostate gland
- Patient to be 18 years and above
Exclusion
- Previous systemic therapy for prostate cancer
- Previous history of another form of cancer (not prostate) within 5 years of study start.
Key Trial Info
Start Date :
October 1 1995
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
1218 Patients enrolled
Trial Details
Trial ID
NCT00672282
Start Date
October 1 1995
End Date
August 1 2008
Last Update
May 27 2009
Active Locations (54)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aalborg, Denmark
2
Research Site
Charlottenlund, Denmark
3
Research Site
Copenhagen, Denmark
4
Research Site
Esbjerg, Denmark